TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of cryothermal applications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications related to cryothermy
Endpoint domain: Adverse events/effects
Primary endpoint: Total inhaled bioavailability of B-17-MP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ventricular tachycardia pace termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time required to stop ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite immune response against toxins A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptable intubation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BADDS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD‐RS‐IV score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with BADDS total score < 50
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in HAMD-S scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment discontinuation due to unwanted symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in algometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelium-dependent arterial function (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum-estradiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reduced conditioned genital responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced subjective sexual responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of coronary artery calcification (CAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage overweight children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 20 m shuttle run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fat absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absorption of fatty acids (AA and DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: trunk coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic intracranial hemorrhage within 72 hours
Endpoint domain: Adverse events/effects
Primary endpoint: mean urinary albumin excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean p-potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowered serum triglyceride (TG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endotoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to achieve best possible outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement of GO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with beneficial improvement in GO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean digital blood flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum detrusor pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor overactivity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean temperature of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes toward feeding and communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Involvement with infant
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Risk of reintervention
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in anti-Müllerian hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 30-day hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD34+ counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF‐I levels in boys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Protein energy percentage (PE%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean level of carotenoids and red-cell folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in controlling hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of venlafaxine
Endpoint domain: Adverse events/effects
Primary endpoint: LDL-cholesterol (LDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MDS TBR of the index vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MDS TBR of the aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ADAS-cog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma malondialdehyde concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major cardiac events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Coronary artery disease (CAD) > 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integration and survivability of the grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attempted sexual intercourse at least once
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Strength (1-RM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in minimum lumen diameter (MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical coronary events (need for revascularization, nonfatal acute myocardial infarction, and coronary death)
Endpoint domain: Mortality/survival
Primary endpoint: Primary end point rate
Endpoint domain: Mortality/survival
Primary endpoint: Survival predictive hazard ratios for CRP and CA19-9
Endpoint domain: Mortality/survival
Primary endpoint: elbow range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (RQLQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Onset of new sensitizations
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of severe haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of urinary fistulas
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of reoperation for complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nausea, vomiting, and pruritus
Endpoint domain: Adverse events/effects
Primary endpoint: long-term clinical outcomes with mandibular overdentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alfa ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from low-back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: visual acuity outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NACE (composite of all-cause death, any stroke, any myocardial infarction, all revascularization, and bleeding)
Endpoint domain: Mortality/survival
Primary endpoint: Lipoprotein(a) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged occlusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced von Willebrand Factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability of the decision aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the decision aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time saved using the decision aid
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean central flap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maximum deviation from intended flap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percentage of measurements with deviation greater than 20 µm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RFBMs per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of subsequent injections resulting in RFBMs within 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Communication with sexual partners about HIV status
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Timed Up and Go (TUG) Test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed graft function (DGF) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum C-reactive protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Soluble intercellular adhesion molecule-1 (sICAM-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in body pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in emotional role
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean number of days to first BPAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage decrease in CMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-48) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of coronary abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean duration of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laboratory indexes of acute inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: study success (alkaline hematin ≤80 mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive peritoneal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: lymphovascular space invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: insulin level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of convulsive activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of propofol requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Formation of capillaries around the site of injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: pain score during therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall HR-QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Capacity HR-QOL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Impact on diagnostic thinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on patient management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or neurosensory disability
Endpoint domain: Mortality/survival
Primary endpoint: aPTT prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Suppression of Insulin Autoantibodies (IAAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Half-life of GSK2618960
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal inhibition of IL-7-mediated STAT5 phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Times to response after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of anterior rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of instrumental deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rates of cesarean section deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decrease in malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in oxidized LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perimetric motion thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of recombinant human FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cholesteryl ester transfer protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high-density lipoprotein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma alpha-tocopherol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slippage with removal
Endpoint domain: Adverse events/effects
Primary endpoint: Pain or discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Total immunoreactivity of FK506
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in erosion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: needle prick injury rate
Endpoint domain: Adverse events/effects
Primary endpoint: direct material cost
Endpoint domain: Resource use
Primary endpoint: Cognitive impairment as a predictor of future functional impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reporting of fire station BP checks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-tidal carbon dioxide concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Normal EF domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferative ability of LAK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SOD-like substance activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: additional daily food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postpartum visit attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Preference for pens over vial-and-syringe
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: all-cause and cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in parent-adolescent relations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in diabetes-specific conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: daytime ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: body mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level during procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer days engaging in condomless sex with casual partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: prednisone bursts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: nocturnal awakenings caused by asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affective empathy responses to facial displays of emotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of RLS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intention-to-treat objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of post-CO2 laser resurfacing hyperpigmentation
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in MetS Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average number of cardiometabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to rescue medication (0-8 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to meaningful pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MPID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mammography screening utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total health care costs
Endpoint domain: Resource use
Primary endpoint: periodontal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels at the first 2 postoperative days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain medication requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfactory bacteriological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception
Endpoint domain: Adverse events/effects
Primary endpoint: Stool frequency greater than three movements per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum tolerable volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: remaining rPF survival
Endpoint domain: Mortality/survival
Primary endpoint: Consumption of junk food and high-fat meat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes